WO2024261740 - SOLID STATE FORMS OF SUNVOZERTINIB
National phase entry is expected:
Publication Number
WO/2024/261740
Publication Date
26.12.2024
International Application No.
PCT/IB2024/056133
International Filing Date
24.06.2024
Title **
[English]
SOLID STATE FORMS OF SUNVOZERTINIB
[French]
FORMES À L'ÉTAT SOLIDE DE SUNVOZERTINIB
Applicants **
ASSIA CHEMICAL INDUSTRIES, LTD.
124 Dvora HaNevi'a St.
6944020 Tel Aviv, IL
Inventors
MUTHUSAMY, Anantha Rajmohan
104 Amman KovilPatti South Street
Virudhunagar
Tamil Nadu 626189, IN
SINGH, Amit
E-301, Ace Platinum, Sector-Zeta-1
Greater Noida
Uttar Pradesh 201306, IN
S, Azhaguraja
Suttikaladipatty, Post-Kottur, Taluk- Nilakottai
Dist. Dindigul
Tamil Nadu 624215, IN
SHARMA, Vikas
Dalelgarh, Post- Bilaspur, Gautam Buddh Nagar
Greater Noida
Uttar Pradesh 203131, IN
Priority Data
202311041887
23.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 993 | |
| EPO | Filing, Examination | 4646 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5035 |
Total: 11780 USD
Abstract[English]
The present disclosure relates to solid state forms of Sunvozertinib and pharmaceutical compositions thereof.[French]
La présente divulgation concerne des formes à l'état solide de Sunvozertinib et des compositions pharmaceutiques associées.